MARK2 and lymphoma: Five genes had recurrent NSVs acquired at the transformation stage: FRYL (MLL fusion partner in lymphoid leukemia), HNF1B (transcription factor whose expression is altered in some cancers), PER3 (checkpoint protein that plays an important role in checkpoint activation, cell proliferation and apoptosis), PIM1 (proto-oncogene with serine/threonine kinase activity involved in the pathogenesis of lymphoma) and PTPRD (tumor suppressor that contributes to the development of multiple cancers).